Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	2.74B -25.1%
Revenue (ttm)	1.00B +28.5%
Net Income	22.39M
EPS	0.17
Shares Out	127.83M
PE Ratio	124.24
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,370,274
Open	22.40
Previous Close	22.13
Day's Range	20.94 - 22.40
52-Week Range	16.10 - 30.48
Beta	0.24
Analysts	Buy
Price Target	31.79 (+48.41%)
Earnings Date	Feb 24, 2026

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glome...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 710
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://apellis.com

Analyst Summary

According to 20 analysts, the average rating for APLS stock is "Buy." The 12-month stock price target is $31.79, which is an increase of 48.41% from the latest price.

Price Target

$31.79

(48.41% upside)

Analyst Consensus: Buy